



Rabies Work Group Update

ACIP Meeting

February 27, 2020

Sharon Frey, MD FACP, FIDSA

Chair, ACIP Rabies Work Group

Work Group Members

ACIP Members

Sharon Frey (chair)

Lynn Bahta

José R. Romero

Liaison Representatives

AAP- Elizabeth Bennett

AAFP- James Stevermer

NACCHO- Matt Zahn

APhA- Karl Hess

NACI- Julie Emili and Linlu Zhao

FDA- Paula Agger and Robin Levis

NASPHV- Katie Brown and Sally Slavinski

NIH- Eun-Chung Park

APHL-Michael Pentella

Invited Consultants

Subject Matter Expert- Deborah Briggs

Subject Matter Expert- Susan Moore

Travel medicine- David Shlim

Emergency Medicine – David Moran

CDC

*Rabies Work Group leads – Jesse Blanton
and Agam Rao*

*Division of Global Migration and
Quarantine- Kristina Angelo*

Immunization Safety Office – Pedro Moro

CDC Technical Work Group and Subject Matter Experts

Brett Petersen

Ryan Wallace

James Ellison

Sathesh Panayampalli

Jesse Bonwitt

Erin Whitehouse

Caroline Schrod

Terms of Reference Abbreviated

- Determine the epidemiology and burden of rabies exposures and PreP and PEP administration in the United States
- Evaluate and revise recommendations as needed for vaccination schedules, route and site of PrEP and PEP
- Consider evidence that was generated to inform the rabies recommendations of other global organizations
- Review rabies exposure risk and risk assessment guidelines for the general population and by occupational and recreational groups

Terms of Reference Continued

- Evaluate serological and monitoring recommendations including whether recommendations should differ depending on the degree of rabies risk for a person and whether adequate antibody titers are needed to confirm immunization
- Consider whether any recommendations should differ for healthy adults compared to immunocompromised persons, children and pregnant women
- Update recommendations with information about the 2 rabies immune globulin products approved by the US FDA during 2018
- Identify areas in need of further research for informing future vaccine and immune globulin recommendations

Recap of Last ACIP Meeting

- Background: epidemiology, clinical course, and rabies biologics in U.S.
- Factors that contribute to decisions for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP)
- Role of neutralizing antibodies as a marker for adequate vaccine response
- Introduction to PrEP schedule considerations
 - Immunogenicity and duration of immunity
 - Route of vaccine administration
 - Role of booster doses for select populations
 - Reasons for PrEP failures

Work Group Activities Since Last ACIP Meeting

- Concluded data review and discussions about PrEP topics
- Began discussing PEP topics
 - PEP schedules
 - Data about rabies immune globulin (RIG) administration
 - Presentations about newly licensed RIG products

Overview of Today's Session: Rabies PrEP

- Background to PrEP, vaccine safety, and WG considerations
- Rabies vaccine schedule and duration of immunity (systematic review data)
- Other guidance and next steps

Tentative Timeline

- February 2020: PrEP data including clinical guidance
- June 2020
 - PrEP GRADE and EtR
 - Some PEP data
- October 2020
 - PrEP vote
 - PEP data including GRADE and EtR
- February 2021: PEP vote

Thank you!

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

